

IAEA/ESNM Webinar Series on basic NM

The (Patho)physiology of Bone Turnover

Suggested Reading

1. Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. *Nat Medicine* 2013; 19: 179-192.
2. Boskey AL. Bone composition: relationship to bone fragility and antiosteoporotic drug effects. *BoneKEy Reports* 2013; 2: 447.
3. Boyle WJ et al. Osteoclast differentiation and activation. *Nature* 2003; 423: 337-342.
4. Clarke B, et al. Normal bone anatomy and physiology. *Clin J Am Soc Nephrol* 2008; 3: S131-S139.
5. Coleman R, et al. Consensus on the utility of bone markers in the malignant bone disease setting. *Crit Rev Oncol Hematol* 2011; 80: 411-32.
6. Day TH, Yang Y. Wnt and hedgehog signaling pathways in bone development. *J Bone Joint Surg Am* 2008; 90(Suppl 1): 19-24.
7. Einhorn TA, Gerstenfeld LC. Fracture healing: mechanisms and interventions. *Nat Rev Rheumatol* 2015; 11: 45-54.
8. Fogelman I, Gnanasegaran G, Van der Wall H. *Radionuclide and Hybrid Bone Imaging*. Berlin and Heidelberg: Springer-Verlag 2013.
9. Fohr B, et al. Clinical review 165: Markers of bone remodeling in metastatic bone disease. *J Clin Endocrinol Metab* 2003; 88: 5059-5075.
10. Franceschi C, et al. Inflamm-aging. An evolutionary perspective on immunosenescence. *Ann NY Acad Sci* 2000; 908: 244-254.
11. Hartman C. A Wnt canon orchestrating osteoblastogenesis. *TRENDS in Cell Biology* 2006; 16: 151-158.
12. Komatsu N, et al. Inflammation and bone destruction in arthritis: synergistic activity of immune and mesenchymal cells in joints. *Front Immunol* 2012; 3: 77.
13. Liu-Bryan R, et al. Emerging regulators of the inflammatory process in osteoarthritis. *Nat Rev Rheumatol* 2015; 11: 35-44.
14. Long F. Building strong bones: molecular regulation of the osteoblast lineage. *Nat Mol Cell Biol* 2012; 13: 27-38.
15. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. *Endocrine Rev* 2000; 21: 115-137.
16. Marriott I. Apoptosis-associated uncoupling of bone formation and resorption in osteomyelitis. *Front Cell Infect Microbiol* 2013; 3: 101.
17. Parfitt AM. Targeted and nontargeted bone remodeling: relationship to basic multicellular unit origination and progression. *Bone* 2002; 30: 5-7.
18. Pietschmann P, et al. Immunology of Osteoporosis: A Mini-Review. *Gerontology* 2015: DOI: 10.1159/000431091.
19. Roodman GD. Mechanisms of bone metastasis. *N Engl J Med* 2004; 350: 1655-1664.
20. Roodman GD. Pathogenesis of myeloma bone disease. *Leukemia* 2009; 23: 435-441.
21. Stegen S, et al. Bringing new life to damaged bone: the importance of angiogenesis in bone repair and regeneration. *Bone* 2015; 70: 19-27.

22. Ubara Y, et al. Histomorphometric features of bone in patients with primary and secondary hypoparathyroidism. *Kidney Int* 2003; 63: 1809-16.
23. Waldvogel FA, et al. Osteomyelitis: a review of clinical features, therapeutic considerations and unusual aspects. *N Engl J Med* 1970; 282: 198-206.
24. Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. *Nat Rev Cancer* 2011; 11: 411-425.
25. Yasuda H, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. *Proc Natl Acad Sci USA* 1998; 95: 3597–3602.